Nurix Therapeutics Inc. (NRIX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nurix Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 69 | $1,240.14 | $1,780.54 | $540.4 | 43.58% |
| BG Bart Gancher Intech Investment Management LLC | 18,559 | $220,480.92 | $473,811.27 | $253,330.35 | 114.9% |
 John H. Burbank III Passport Capital LLC | 4.66M | $115.95M | $118.51M | $2.56M | 2.21% |
 Point72 Asset Management LP Point72 Asset Management LP | 73,069 | $1.39M | $1.98M | $590,397.44 | 42.59% |
| NM Nir Messafi Deep Track Capita LLP | 7.74M | $122.06M | $199.56M | $77.5M | 63.49% |
Nurix Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GR Gregory Renza Truist Securities | 151.43 | $2,368.38 | $3,885.71 | $1,517.33 | 64.07% |
Nurix Therapeutics Inc. (NRIX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nurix Therapeutics Inc. ever had a stock split?
Nurix Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Arthur T. Sands CEO | NASDAQ (NMS) Exchange | 67080M103 CUSIP |
| US Country | 317 Employees | - Last Dividend | - Last Split | 24 Jul 2020 IPO Date |
Overview
Nurix Therapeutics, Inc. is a pioneering clinical stage biopharmaceutical company committed to the discovery, development, and eventual commercialization of novel small molecule and cell therapies aimed at cancer, inflammatory conditions, and various other diseases. Having undergone a name change from Nurix Inc. to Nurix Therapeutics, Inc. in October 2018, the company has been forging significant strides since its inception in 2009. With its headquarters rooted in San Francisco, California, Nurix stands out through its strategic collaborations with industry giants such as Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc., aiming for the co-development and co-commercialization of multiple promising drug candidates.
Products and Services
- NX-2127: An innovative, orally bioavailable Bruton's tyrosine kinase (BTK) degrader designed for the treatment of relapsed or refractory B-cell malignancies. NX-2127 represents a new breed of cancer therapy, targeting and degrading BTK, a key protein involved in the growth and survival of malignant B cells.
- NX-5948: This orally bioavailable BTK degrader is being developed for patients suffering from relapsed or refractory B-cell malignancies and autoimmune diseases. By targeting the same BTK protein as NX-2127, NX-5948 underscores Nurix’s commitment to innovating within this therapeutic space, potentially offering a broader scope of treatment for patients with complex conditions.
- NX-1607: A pioneering, orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor focused on immuno-oncology indications. NX-1607's mechanism involves the inhibition of CBL-B, a protein that plays a crucial role in immune cell regulation. This approach aims to unleash the body's immune response against cancer cells, opening new avenues for cancer therapy.
- NX-0479/GS-6791: A cutting-edge IRAK4 degrader developed for the treatment of rheumatoid arthritis and other inflammatory diseases. This product underscores Nurix's expansion into inflammatory diseases, targeting IRAK4, a protein involved in inflammation signaling pathways, thereby addressing a critical need in the management of such conditions.
